

Contents

Preface xv
Acknowledgements xvi

Section 1 General principles

1 What is pharmacology? 1

- Overview 1
- What is a drug? 1
- Origins and antecedents 1
- Pharmacology in the 20th and 21st centuries 2
 - Alternative therapeutic principles 2
 - The emergence of biotechnology 3
 - Pharmacology today 4

2 How drugs act: general principles 6

- Overview 6
- Introduction 6
- Protein targets for drug binding 6
 - Drug receptors 6
 - Drug specificity 7
 - Receptor classification 8
 - Drug-receptor interactions 8
 - Competitive antagonism 10
 - Partial agonists and the concept of efficacy 11
 - Partial agonists as antagonists 13
 - Other forms of drug antagonism 16
- Desensitisation and tolerance 18
 - Change in receptors 18
 - Translocation of receptors 19
 - Exhaustion of mediators 19
 - Altered drug metabolism 19
 - Physiological adaptation 19
- Quantitative aspects of drug-receptor interactions 19
 - The binding reaction 19
 - Binding when more than one drug is present 20
- The nature of drug effects 21

3 How drugs act: molecular aspects 23

- Overview 23
- Protein targets for drug action 23
 - Receptors 23
 - Ion channels 23
 - Enzymes 24
 - Transporters 24
- Receptor proteins 25
 - Cloning of receptors 25
 - Types of receptor 25
 - Molecular structure of receptors 26
 - Type 1: Ligand-gated ion channels 27
 - Type 2: G protein-coupled receptors 29
 - Type 3: Kinase-linked and related receptors 40
 - Type 4: Nuclear receptors 44
- Ion channels as drug targets 46
 - Ion selectivity 47
 - Gating 47

- Molecular architecture of ion channels 48
- Pharmacology of ion channels 49
- Control of receptor expression 49
- Receptors and disease 49

4 How drugs act: cellular aspects – excitation, contraction and secretion 52

- Overview 52
- Regulation of intracellular calcium 52
 - Calcium entry mechanisms 52
 - Calcium extrusion mechanisms 55
 - Calcium release mechanisms 55
 - Calmodulin 56
- Excitation 56
 - The 'resting' cell 57
 - Electrical and ionic events underlying the action potential 57
 - Channel function 58
- Muscle contraction 61
 - Skeletal muscle 62
 - Cardiac muscle 64
 - Smooth muscle 64
- Release of chemical mediators 64
 - Exocytosis 65
 - Non-vesicular release mechanisms 66
- Epithelial ion transport 67

5 How drugs act: biopharmaceuticals and gene therapy 69

- Overview 69
- Introduction 69
- Protein and oligonucleotide biopharmaceuticals 69
- Proteins and polypeptides 70
 - Monoclonal antibodies 71
- Oligonucleotides 72
 - Pharmacology of protein and oligonucleotide pharmaceuticals 73
- Gene therapy 74
 - Gene delivery 75
 - Controlling gene expression 77
- Safety and societal issues 77
- Therapeutic applications 77
- Concluding remarks 79

6 Cell proliferation, apoptosis, repair and regeneration 82

- Overview 82
- Cell proliferation 82
 - The cell cycle 82
 - Interactions between cells, growth factors and the extracellular matrix 85
- Angiogenesis 86
- Apoptosis and cell removal 86
 - Morphological changes in apoptosis 87
 - The major players in apoptosis 87

- Pathways to apoptosis 88
- Pathophysiological implications 89**
 - Repair and healing 89
 - Hyperplasia 89
 - The growth, invasion and metastasis of tumours 89
 - Stem cells and regeneration 90
- Therapeutic prospects 90**
 - Apoptotic mechanisms 90
 - Angiogenesis and metalloproteinases 91
 - Cell cycle regulation 91

7 Cellular mechanisms: host defence 93

- Overview 93**
- Introduction 93**
- The innate immune response 93**
 - Pattern recognition 93
- The adaptive immune response 98**
 - The induction phase 99
 - The effector phase 100
- Systemic responses in inflammation 103**
 - The role of the nervous system in inflammation 103
 - Unwanted inflammatory and immune responses 103
 - The outcome of the inflammatory response 104

8 Method and measurement in pharmacology 106

- Overview 106**
- Bioassay 106**
 - Biological test systems 106
 - General principles of bioassay 107
- Animal models of disease 110**
 - Genetic and transgenic animal models 110
- Pharmacological studies in humans 111**
- Clinical trials 111**
 - Avoidance of bias 112
 - The size of the sample 113
 - Clinical outcome measures 114
 - Placebos 114
 - Meta-analysis 114
 - Balancing benefit and risk 114

9 Absorption and distribution of drugs 117

- Overview 117**
- Introduction 117**
- Physical processes underlying drug disposition 117**
 - The movement of drug molecules across cell barriers 117
 - Binding of drugs to plasma proteins 121
 - Partition into body fat and other tissues 124
- Drug absorption and routes of administration 124**
 - Oral administration 124
 - Oromucosal (sublingual or buccal) administration 126
 - Rectal administration 127
 - Application to epithelial surfaces 127
- Distribution of drugs in the body 128**
 - Body fluid compartments 128

- Volume of distribution 129
- Special drug delivery systems 131

10 Drug metabolism and elimination 133

- Overview 133**
- Introduction 133**
 - Drug metabolism 133
 - Phase 1 reactions 133
 - Phase 2 reactions 135
 - Stereoselectivity 135
 - Inhibition of P450 136
 - Induction of microsomal enzymes 136
 - Presystemic ('first-pass') metabolism 136
 - Pharmacologically active drug metabolites 137
 - Drug interactions due to enzyme induction or inhibition 137
- Drug and metabolite excretion 139**
 - Biliary excretion and enterohepatic circulation 139
 - Renal excretion of drugs and metabolites 139
 - Drug interactions due to altered drug excretion 140

11 Pharmacokinetics 143

- Overview 143**
- Introduction: definition and uses of pharmacokinetics 143**
 - Uses of pharmacokinetics 144
 - Scope of this chapter 144
- Drug elimination expressed as clearance 144**
- Single-compartment model 145**
 - Effect of repeated dosing 146
 - Effect of variation in rate of absorption 146
- More complicated kinetic models 147**
 - Two-compartment model 148
 - Saturation kinetics 149
- Population pharmacokinetics 149**
- Limitations of pharmacokinetics 150**

12 Individual variation, pharmacogenomics and personalised medicine 152

- Overview 152**
- Introduction 152**
- Epidemiological factors and inter-individual variation of drug response 153**
 - Ethnicity 153
 - Age 153
 - Pregnancy 155
 - Disease 155
 - Drug interactions 155
- Genetic variation in drug responsiveness 156**
 - Single-gene pharmacokinetic disorders 157
- Therapeutic drugs and clinically available pharmacogenomic tests 159**
 - HLA gene tests 159
 - Drug metabolism-related gene tests 160
 - Drug target-related gene tests ('companion diagnostics') 161
 - Combined (metabolism and target) gene tests 161
- Conclusions 161**

Section 2 Chemical mediators

13 Chemical mediators and the autonomic nervous system 163

Overview 163

Historical aspects 163

The autonomic nervous system 164

Basic anatomy and physiology 164

Transmitters in the autonomic nervous system 165

Some general principles of chemical transmission 167

Presynaptic modulation 167

Postsynaptic modulation 169

Transmitters other than acetylcholine and noradrenaline 170

Co-transmission 170

Termination of transmitter action 170

Denervation supersensitivity 171

Basic steps in neurochemical transmission: sites of drug action 173

14 Cholinergic transmission 175

Overview 175

Muscarinic and nicotinic actions of acetylcholine 175

Acetylcholine receptors 175

Nicotinic receptors 175

Muscarinic receptors 177

Physiology of cholinergic transmission 178

Acetylcholine synthesis and release 178

Electrical events in transmission at fast cholinergic synapses 180

Effects of drugs on cholinergic transmission 181

Drugs affecting muscarinic receptors 181

Drugs affecting autonomic ganglia 185

Drugs that act presynaptically 190

Drugs that enhance cholinergic transmission 192

Other drugs that enhance cholinergic transmission 196

15 Noradrenergic transmission 197

Overview 197

Catecholamines 197

Classification of adrenoceptors 197

Physiology of noradrenergic transmission 198

The noradrenergic neuron 198

Uptake and degradation of catecholamines 201

Drugs acting on noradrenergic transmission 202

Drugs acting on adrenoceptors 202

Drugs that affect noradrenergic neurons 213

16 5-Hydroxytryptamine and the pharmacology of migraine 217

Overview 217

5-Hydroxytryptamine 217

Distribution, biosynthesis and degradation 217

Pharmacological effects 221

Drugs acting at 5-HT receptors 221

Migraine and other clinical conditions in which 5-HT plays a role 223

Migraine and antimigraine drugs 223

Antimigraine drugs 224

Carcinoid syndrome 224

Pulmonary hypertension 225

17 Purines 228

Overview 228

Introduction 228

Purinergic receptors 228

Adenosine as a mediator 228

Adenosine and the cardiovascular system 230

Adenosine in asthma 231

Adenosine in inflammation 231

Adenosine in the CNS 231

ADP as a mediator 231

ADP and platelets 231

ATP as a mediator 231

ATP as a neurotransmitter 231

ATP in nociception 232

ATP in inflammation 232

Future prospects 232

18 Local hormones 1: histamine and the biologically active lipids 233

Overview 233

Introduction 233

What is a 'mediator'? 233

Histamine 233

Synthesis and storage of histamine 234

Histamine release 234

Histamine receptors 234

Actions 234

Eicosanoids 235

General remarks 235

Structure and biosynthesis 235

Prostanoids 235

Leukotrienes 240

Leukotriene receptors 240

Leukotriene actions 241

Other important fatty acid derivatives 241

Platelet-activating factor 242

Biosynthesis 242

Actions and role in inflammation 242

Concluding remarks 242

19 Local hormones 2: peptides and proteins 244

Overview 244

Introduction 244

General principles of protein and peptide pharmacology 244

Structure 244

Types of protein and peptide mediator 244

Biosynthesis and regulation of peptides 245

Peptide precursors 246

Diversity within peptide families 246

Peptide trafficking and secretion 246

Bradykinin 247

Source and formation of bradykinin 247

Metabolism and inactivation of bradykinin 247

- Bradykinin receptors 247
 - Actions and role in inflammation 247
- Neuropeptides 248
- Cytokines 248
 - Interleukins and related compounds 249
 - Chemokines 249
 - Interferons 249
 - The 'cytokine storm' 251
- Proteins and peptides that down-regulate inflammation 251
- Concluding remarks 251

20 Cannabinoids 253

- Overview 253
- Plant-derived cannabinoids and their pharmacological effects 253
 - Pharmacological effects 253
 - Pharmacokinetic aspects 253
 - Adverse effects 253
 - Tolerance and dependence 254
- Cannabinoid receptors 254
- Endocannabinoids 255
 - Biosynthesis of endocannabinoids 255
 - Termination of the endocannabinoid signal 256
 - Physiological mechanisms 257
 - Pathological involvement 257
- Synthetic cannabinoids 258
- Clinical applications 258

21 Nitric oxide and related mediators 260

- Overview 260
- Introduction 260
- Biosynthesis of nitric oxide and its control 260
- Degradation and carriage of nitric oxide 262
- Effects of nitric oxide 263
 - Biochemical and cellular aspects 263
 - Vascular effects 264
 - Neuronal effects 264
 - Host defence 264
- Therapeutic aspects 265
 - Nitric oxide 265
 - Nitric oxide donors/precursors 265
 - Inhibition of nitric oxide synthesis 265
 - Nitric oxide replacement or potentiation 266
- Clinical conditions in which nitric oxide may play a part 266
- Related mediators 267

Section 3 Drugs affecting major organ systems

22 The heart 271

- Overview 271
- Introduction 271
- Physiology of cardiac function 271
 - Cardiac rate and rhythm 271
 - Cardiac contraction 274
 - Myocardial oxygen consumption and coronary blood flow 275

- Autonomic control of the heart 276
 - Sympathetic system 276
 - Parasympathetic system 277
- Cardiac natriuretic peptides 278
- Ischaemic heart disease 278
 - Angina 278
 - Myocardial infarction 279
- Drugs that affect cardiac function 279
 - Antidysrhythmic drugs 279
 - Drugs that increase myocardial contraction 283
 - Anti-anginal drugs 284

23 The vascular system 290

- Overview 290
- Introduction 290
- Vascular structure and function 290
- Control of vascular smooth muscle tone 291
 - The vascular endothelium 291
 - The renin-angiotensin system 295
- Vasoactive drugs 296
 - Vasoconstrictor drugs 296
 - Vasodilator drugs 297
- Clinical uses of vasoactive drugs 301
 - Systemic hypertension 301
 - Heart failure 304
 - Vasodilatory shock and hypotensive states 306
 - Peripheral vascular disease 307
 - Raynaud's disease 307
 - Pulmonary hypertension 307

24 Atherosclerosis and lipoprotein metabolism 310

- Overview 310
- Introduction 310
- Atherogenesis 310
- Lipoprotein transport 311
 - Dyslipidaemia 312
- Prevention of atheromatous disease 313
- Lipid-lowering drugs 314
 - Statins: HMG-CoA reductase inhibitors 314
 - Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors 315
 - Fibrates 315
 - Drugs that inhibit cholesterol absorption 316
 - Nicotinic acid 316
 - Fish oil derivatives 316
 - Mipomersen 317
 - Lomitapide 317

25 Haemostasis and thrombosis 319

- Overview 319
- Introduction 319
- Blood coagulation 319
 - Coagulation cascade 319
 - Vascular endothelium in haemostasis and thrombosis 321
- Drugs that act on the coagulation cascade 322
 - Coagulation defects 322
 - Thrombosis 323
- Platelet adhesion and activation 327
 - Antiplatelet drugs 329
- Fibrinolysis (thrombolysis) 330
 - Fibrinolytic drugs 331

26 Haematopoietic system and treatment of anaemia 334

- Overview 334
- Introduction 334
- The haematopoietic system 334
- Types of anaemia 334
- Haematinic agents 335
 - Iron 335
 - Folic acid and vitamin B₁₂ 337
- Haematopoietic growth factors 338
- Haemolytic anaemia 341
 - Drugs used to treat haemolytic anaemias 341

27 Anti-inflammatory and immunosuppressant drugs 343

- Overview 343
- Introduction 343
- Cyclo-oxygenase inhibitors 343
 - Mechanism of action 344
 - Pharmacological actions 345
 - Therapeutic actions 346
 - Some important NSAIDs and coxibs 348
- Antirheumatoid drugs 351
- Anticytokine drugs and other biopharmaceuticals 355
- Drugs used in gout 356
- Antagonists of histamine 358
- Possible future developments in anti-inflammatory therapy 359

28 Skin 362

- Overview 362
- Introduction 362
- Structure of skin 362
- Common diseases of the skin 364
 - Acne 364
 - Rosacea 365
 - Baldness and hirsutism 365
 - Eczema 365
 - Pruritus 365
 - Urticaria 365
 - Psoriasis 366
 - Warts 366
 - Other infections 366
- Drugs acting on skin 366
 - Formulation 366
- Principal drugs used in skin disorders 366
 - Antimicrobial agents 366
 - Glucocorticoids and other anti-inflammatory agents 367
 - Drugs used to control hair growth 367
 - Retinoids 368
 - Vitamin D analogues 369
- Agents acting by other mechanisms 369
- Concluding remarks 369

29 Respiratory system 371

- Overview 371
- The physiology of respiration 371
 - Control of breathing 371
 - Regulation of musculature, blood vessels and glands of the airways 371

- Pulmonary disease and its treatment 372
 - Bronchial asthma 372
 - Drugs used to treat and prevent asthma 375
 - Severe acute asthma (status asthmaticus) 379
 - Allergic emergencies 379
 - Chronic obstructive pulmonary disease 379
 - Idiopathic pulmonary fibrosis 380
 - Surfactants 380
 - Cough 380

30 The kidney and urinary system 382

- Overview 382
- Introduction 382
- Outline of renal function 382
- The structure and function of the nephron 382
 - Tubular function 384
 - Acid–base balance 387
 - Potassium balance 388
 - Excretion of organic molecules 388
 - Natriuretic peptides 388
 - Prostaglandins and renal function 388
- Drugs acting on the kidney 388
 - Diuretics 388
- Drugs that alter the pH of the urine 392
- Drugs that alter the excretion of organic molecules 392
- Drugs used in renal failure 393
 - Hyperphosphataemia 393
 - Hyperkalaemia 393
- Drugs used in urinary tract disorders 393

31 The gastrointestinal tract 395

- Overview 395
- The innervation and hormones of the gastrointestinal tract 395
 - Neuronal control 395
 - Hormonal control 395
- Gastric secretion 395
 - The regulation of acid secretion by parietal cells 395
 - The coordination of factors regulating acid secretion 396
 - Drugs used to inhibit or neutralise gastric acid secretion 397
 - Treatment of *Helicobacter pylori* infection 399
 - Drugs that protect the mucosa 400
- Vomiting 400
 - The reflex mechanism of vomiting 400
 - Antiemetic drugs 401
- The motility of the GI tract 403
 - Purgatives 404
 - Drugs that increase gastrointestinal motility 404
 - Antidiarrhoeal agents 405
- Drugs for chronic bowel disease 406
- Drugs affecting the biliary system 406
- Future directions 407

32 The control of blood glucose and drug treatment of diabetes mellitus 408

- Overview 408
- Introduction 408
- Control of blood glucose 408

- Pancreatic islet hormones **409**
 Insulin 410
 Glucagon 412
 Somatostatin 413
 Amylin (islet amyloid polypeptide) 413
 Incretins 413
 Diabetes mellitus **413**
 Drugs used in the treatment of diabetes 414
 Treatment of diabetes mellitus 419

33 Obesity 422

- Overview **422**
 Introduction **422**
 Definition of obesity 422
 Obesity as a health problem **422**
 Homeostatic mechanisms controlling energy balance **423**
 The role of gut and other hormones in body weight regulation 423
 Neurological circuits that control body weight and eating behaviour 423
 The pathophysiology of human obesity **426**
 Food intake and obesity 426
 Physical exercise and obesity 427
 Obesity as a disorder of the homeostatic control of energy balance 427
 Genetic factors and obesity 427
 Pharmacological approaches to the problem of obesity **428**
 Centrally acting appetite suppressants 429
 Orlistat 429
 New approaches to obesity therapy **430**

34 The pituitary and the adrenal cortex 432

- Overview **432**
 The pituitary gland **432**
 The anterior pituitary gland 432
 Hypothalamic hormones 432
 Anterior pituitary hormones 433
 Posterior pituitary gland 437
 The adrenal cortex **438**
 Glucocorticoids 440
 Mineralocorticoids 444
 New directions in glucocorticoid therapy **445**

35 The thyroid 448

- Overview **448**
 Synthesis, storage and secretion of thyroid hormones **448**
 Uptake of plasma iodide by the follicle cells 448
 Oxidation of iodide and iodination of tyrosine residues 448
 Secretion of thyroid hormone 448
 Regulation of thyroid function **448**
 Actions of the thyroid hormones **450**
 Effects on metabolism 450
 Effects on growth and development 451
 Mechanism of action 451
 Transport and metabolism of thyroid hormones **451**
 Abnormalities of thyroid function **451**
 Hyperthyroidism (thyrotoxicosis) 451
 Simple, non-toxic goitre 452
 Hypothyroidism 452

- Drugs used in diseases of the thyroid **452**
 Hyperthyroidism 452
 Hypothyroidism 453

36 The reproductive system 455

- Overview **455**
 Introduction **455**
 Endocrine control of reproduction **455**
 Neurohormonal control of the female reproductive system 455
 Neurohormonal control of the male reproductive system 457
 Behavioural effects of sex hormones 458
 Drugs affecting reproductive function **458**
 Oestrogens 458
 Antioestrogens 459
 Progestogens 459
 Postmenopausal hormone replacement therapy (HRT) 460
 Androgens 461
 Anabolic steroids 461
 Anti-androgens 462
 Gonadotrophin-releasing hormone: agonists and antagonists 462
 Gonadotrophins and analogues 463
 Drugs used for contraception **463**
 Oral contraceptives 463
 Other drug regimens used for contraception 464
 The uterus **465**
 The motility of the uterus 465
 Drugs that stimulate the uterus 465
 Drugs that inhibit uterine contraction 466
 Erectile dysfunction **467**

37 Bone metabolism 470

- Overview **470**
 Introduction **470**
 Bone structure and composition **470**
 Bone remodelling **470**
 The action of cells and cytokines 470
 The turnover of bone minerals 472
 Hormones involved in bone metabolism and remodelling 473
 Disorders of bone **474**
 Drugs used in bone disorders **475**
 Bisphosphonates 475
 Oestrogens and related compounds 476
 Parathyroid hormone and teriparatide 476
 Vitamin D preparations 477
 Biopharmaceuticals 477
 Calcitonin 477
 Calcium salts 477
 Calcimimetic compounds 478
 Potential new therapies **478**

Section 4 Nervous system

38 Chemical transmission and drug action in the central nervous system 480

- Overview **480**
 Introduction **480**

- Chemical signalling in the nervous system **480**
- Targets for drug action **482**
- Drug action in the central nervous system **483**
 - Blood-brain barrier 483
- The classification of psychotropic drugs **484**

39 Amino acid transmitters **486**

- Overview **486**
- Excitatory amino acids **486**
 - Excitatory amino acids as CNS transmitters 486
 - Metabolism and release of excitatory amino acids 486
- Glutamate **487**
 - Glutamate receptor subtypes 487
 - Synaptic plasticity and long-term potentiation 491
 - Drugs acting on glutamate receptors 491
- γ -Aminobutyric acid (GABA) **493**
 - Synthesis, storage and function 493
 - GABA receptors: structure and pharmacology 494
 - Drugs acting on GABA receptors 496
- Glycine **497**
- Concluding remarks **497**

40 Other transmitters and modulators **499**

- Overview **499**
- Introduction **499**
- Noradrenaline **499**
 - Noradrenergic pathways in the CNS 499
 - Functional aspects 500
- Dopamine **500**
 - Dopaminergic pathways in the CNS 501
 - Dopamine receptors 502
 - Functional aspects 502
- 5-Hydroxytryptamine **504**
 - 5-HT pathways in the CNS 504
 - 5-HT receptors in the CNS 504
 - Functional aspects 505
 - Clinically used drugs 506
- Acetylcholine **506**
 - Cholinergic pathways in the CNS 507
 - Acetylcholine receptors 507
 - Functional aspects 507
- Purines **508**
- Histamine **509**
- Other CNS mediators **509**
 - Melatonin 509
 - Nitric oxide 509
 - Lipid mediators 510
- A final message **512**

41 Neurodegenerative diseases **514**

- Overview **514**
- Protein misfolding and aggregation in chronic neurodegenerative diseases **514**
- Mechanisms of neuronal death **514**
 - Excitotoxicity 516
 - Apoptosis 516
 - Oxidative stress 516
- Ischaemic brain damage **518**
 - Pathophysiology 518
 - Therapeutic approaches 519
- Alzheimer's disease **519**
 - Pathogenesis of Alzheimer's disease 519

- Therapeutic approaches 521
- Parkinson's disease **522**
 - Features of Parkinson's disease 522
 - Pathogenesis of Parkinson's disease 523
 - Drug treatment of Parkinson's disease 524
- Huntington's disease **527**
- Amytrophic lateral sclerosis **528**
- Spinal muscular atrophy **528**
- Multiple sclerosis **528**

42 General anaesthetic agents **531**

- Overview **531**
- Introduction **531**
- Mechanism of action of anaesthetic drugs **531**
 - Lipid solubility 531
 - Effects on ion channels 532
 - Effects on the nervous system 533
 - Effects on the cardiovascular and respiratory systems 533
- Intravenous anaesthetic agents **534**
 - Propofol 534
 - Thiopental 534
 - Etomidate 535
 - Other intravenous agents 535
- Inhalation anaesthetics **536**
 - Pharmacokinetic aspects 536
- Individual inhalation anaesthetics **539**
 - Isoflurane, desflurane, sevoflurane, enflurane and halothane 539
 - Nitrous oxide 540
- Balanced anaesthesia **540**

43 Analgesic drugs **542**

- Overview **542**
- Neural mechanisms of pain **542**
 - Nociceptive afferent neurons 542
 - Modulation in the nociceptive pathway 543
 - Neuropathic pain 546
 - Chemical signalling in the nociceptive pathway 546
- Analgesic drugs **548**
 - Opioid drugs 548
 - Paracetamol 559
 - Treatment of chronic pain 559
 - Other pain-relieving drugs 560
 - New approaches 560

44 Local anaesthetics and other drugs affecting sodium channels **563**

- Overview **563**
- Local anaesthetics **563**
 - Chemical aspects 563
 - Mechanism of action 563
 - Pharmacokinetic aspects 566
 - New approaches 566
- Other drugs that affect sodium channels **567**
 - Tetrodotoxin and saxitoxin 567
 - Agents that affect sodium-channel gating 568

45 Anxiolytic and hypnotic drugs **569**

- Overview **569**
- The nature of anxiety and its treatment **569**
- Measurement of anxiolytic activity **569**
 - Animal models of anxiety 569

- Tests on humans 570
- Drugs used to treat anxiety **571**
- Delayed anxiolytic effect of SSRIs and buspirone **572**
 - Benzodiazepines and related drugs 572
 - Other potential anxiolytic drugs 576
- Drugs used to treat insomnia (hypnotic drugs) **577**
 - Induction of sleep by benzodiazepines 578

46 Antiepileptic drugs 580

- Overview **580**
- Introduction **580**
- The nature of epilepsy **580**
 - Types of epilepsy 580
 - Neural mechanisms and animal models of epilepsy 582
- Antiepileptic drugs **582**
 - Carbamazepine 586
 - Phenytoin 586
 - Valproate 587
 - Ethosuximide 588
 - Phenobarbital 588
 - Benzodiazepines 588
 - Newer antiepileptic drugs 589
 - New drugs 590
 - Other uses of antiepileptic drugs 590
 - Antiepileptic drugs and pregnancy 590
- Muscle spasm and muscle relaxants **590**

47 Antipsychotic drugs 592

- Overview **592**
- Introduction **592**
- The nature of schizophrenia **592**
 - Aetiology and pathogenesis of schizophrenia 593
- Antipsychotic drugs **595**
 - Classification of antipsychotic drugs 595
 - Clinical efficacy in treatment of schizophrenia 595
 - Other uses of antipsychotic drugs 598
 - Pharmacological properties 598
 - Unwanted effects 599
 - Pharmacokinetic aspects 601
- Future developments **601**

48 Antidepressant drugs 603

- Overview **603**
- The nature of depression **603**
- Theories of depression **603**
 - The monoamine theory 603
 - Negative affective bias 604
 - Neuroendocrine mechanisms 604
 - Trophic effects and neuroplasticity 605
- Antidepressant drugs **606**
 - Types of antidepressant drug 606
 - Testing of antidepressant drugs 607
 - Mechanism of action of antidepressant drugs 611
 - Monoamine uptake inhibitors 611
 - Monoamine receptor antagonists 616
 - Monoamine oxidase inhibitors 616
 - Melatonin agonist 618
 - Ketamine 618
 - Other antidepressant approaches 618
- Clinical effectiveness of antidepressant treatments **618**
- Future antidepressant drugs **619**
- Brain stimulation therapies **619**
- Drug treatment of bipolar disorder **620**

- Lithium 620
- Antiepileptic drugs 621
- Second-generation antipsychotic drugs 621

49 Psychoactive drugs 623

- Overview **623**
- Introduction **623**
- Psychomotor stimulants **623**
 - Amphetamines 623
 - Methylphenidate 625
 - Modafinil 626
 - Cocaine 626
 - MDMA 628
 - Cathinones 628
 - Methylxanthines 629
 - Nicotine 629
 - Pharmacological effects of nicotine 630
 - Pharmacokinetic aspects 631
 - Tolerance and dependence 631
 - Harmful effects of tobacco smoking 632
- Cognition-enhancing drugs **633**
- Psychedelic drugs **634**
 - LSD, psilocybin and mescaline 634
 - Other psychedelic drugs 635
- Ketamine and related drugs **635**
- Depressants **635**
 - Ethanol 636
 - Pharmacological effects of ethanol 636
 - Pharmacokinetic aspects 638
- Tolerance and dependence **640**
- Synthetic cannabinoids 640

50 Drug abuse and dependence 642

- Overview **642**
- Drug use and abuse **642**
 - Drug administration 642
 - Drug harm 643
 - Drug dependence 643
 - Withdrawal 644
 - Tolerance 646
 - Pharmacological approaches to treating drug dependence 646

Section 5 Drugs used for the treatment of infections and cancer

51 Basic principles of antimicrobial chemotherapy 649

- Overview **649**
- Background **649**
- The molecular basis of chemotherapy **649**
 - Bacteria 649
 - Biochemical reactions as potential targets 650
 - The formed structures of the cell as potential targets 654
- Resistance to antibacterial drugs **656**
 - The spread of antibiotic resistance 656
 - Biochemical mechanisms of resistance to antibiotics 657
- Current status of antibiotic resistance in bacteria **659**

52 Antibacterial drugs 661**Overview 661****Introduction 661**

Antibacterial agents that interfere with folate synthesis or action **661**

Sulfonamides 661

Trimethoprim 662

β -lactam antibiotics and other agents that interfere with bacterial wall or membrane synthesis **663**

Penicillins 663

Cephalosporins and cephamycins 665

Other β -lactam antibiotics 665

Other antibiotics that inhibit bacterial cell wall peptidoglycan synthesis 665

Antimicrobial agents affecting bacterial protein synthesis **666**

Tetracyclines 666

Chloramphenicol 667

Aminoglycosides 667

Macrolides 670

Oxazolidinones 670

Fusidic acid 671

Streptogramins 671

Clindamycin 671

Antimicrobial agents affecting topoisomerase **672**

Quinolones 672

Miscellaneous antibacterial agents **672**

Antimycobacterial agents **673**

Drugs used to treat tuberculosis 673

Drugs used to treat leprosy 675

Possible new antibacterial drugs **675**

53 Antiviral drugs 678**Overview 678**

Background information about viruses **678**

An outline of virus structure 678

Examples of pathogenic viruses 678

Virus function and life history 678

The host-virus interaction **679**

Host defences against viruses 679

Viral ploys to circumvent host defences 680

HIV and AIDS **680**

Induction of the disease 681

Progress of infection 681

Antiviral drugs **681**

Reverse transcriptase inhibitors 684

Non-nucleoside reverse transcriptase inhibitors 684

Protease inhibitors 685

DNA polymerase inhibitors 685

Neuraminidase inhibitors and inhibitors of viral coat disassembly 685

Drugs acting through other mechanisms 686

Biopharmaceutical antiviral drugs 686

Other agents 686

Combination therapy for HIV **687**

Prospects for new antiviral drugs **687**

54 Antifungal drugs 690**Overview 690**

Fungi and fungal infections **690**

Drugs used to treat fungal infections **691**

Antifungal antibiotics 691

Synthetic antifungal drugs 693

Future developments **694**

55 Antiprotozoal drugs 696**Overview 696**

Background **696**

Host-parasite interactions **696**

Malaria and antimalarial drugs **696**

The life cycle of the malaria parasite 698

Antimalarial drugs 699

Potential new antimalarial drugs 705

Amoebiasis and amoebicidal drugs **705**

Trypanosomiasis and trypanocidal drugs **706**

Other protozoal infections and drugs used to treat them **707**

Leishmaniasis 707

Trichomoniasis 707

Giardiasis 708

Toxoplasmosis 708

Pneumocystis 708

Future developments **708**

56 Anthelmintic drugs 710**Overview 710**

Helminth infections **710**

Anthelmintic drugs **711**

Resistance to anthelmintic drugs **713**

Vaccines and other novel approaches **714**

57 Anticancer drugs 716**Overview 716**

Introduction **716**

The pathogenesis of cancer **716**

The genesis of a cancer cell 717

The special characteristics of cancer cells 717

General principles of cytotoxic anticancer drugs **719**

Anticancer drugs **720**

Alkylating agents and related compounds 722

Antimetabolites 723

Cytotoxic antibiotics 724

Plant derivatives 726

Hormones 726

Hormone antagonists 727

Monoclonal antibodies 727

Protein kinase inhibitors 728

Miscellaneous agents 729

Resistance to anticancer drugs 729

Combination therapies 730

Control of emesis and myelosuppression 730

Future developments **730**

Section 6 Special topics**58 Harmful effects of drugs 733****Overview 733**

Introduction **733**

Classification of adverse drug reactions **733**

Adverse effects related to the known pharmacological action of the drug 733

- Adverse effects unrelated to the known pharmacological action of the drug 734
- Drug toxicity 734**
 - Toxicity testing 734
 - General mechanisms of toxin-induced cell damage and cell death 735
 - Mutagenesis and assessment of genotoxic potential 736

- 46 Immunological reactions to drugs 741**
 - Immunological mechanisms 742
 - Clinical types of allergic response to drugs 742

59 Lifestyle and drugs in sport 744

- Overview 744
- What are lifestyle drugs? 744
- Classification of lifestyle drugs 744
- Drugs and sex 745
- Drugs in sport 745
 - Anabolic steroids 746

- Human growth hormone 748
- Stimulant drugs 748
- Conclusion 748

60 Drug discovery and development 750

- Overview 750
- The stages of a project 750
 - The drug discovery phase 750
 - Preclinical development 752
 - Clinical development 753
- Biopharmaceuticals 753
- Commercial aspects 754
- Future prospects 754
- A final word 755

Index 756

Self-assessment questions compiled by Dr. Christine Edmead, University of Bath, are available through <https://studentconsult.inkling.com>

47 Antipsychotic drugs 710

- Overview 710
- Introduction 710
- The nature of antipsychotic drugs 710

48 Antidepressant drugs 726

- Overview 726
- Introduction 726
- The nature of antidepressant drugs 726
- Classification of antidepressant drugs 726
- General principles of cytotoxic anticancer drugs 719
- Anticancer drugs 720
- Allylating agents and topoisomerase inhibitors 723
- Antimetabolites 723
- Cytotoxic antibiotics 726
- Plant derivatives 726
- Hormones 726
- Protein kinase inhibitors 728
- Mitochondrial inhibitors 729
- Miscellaneous agents 729
- Resistance to anticancer drugs 730
- Combination therapy 730
- Control of anti-cancer drug development 730
- Future developments 730
- Testing 730
- Mechanism of action of mitomycin 730

50 Drug abuse and dependence 649

- Overview 649
- Drug abuse and dependence 649
- Background information about viruses 678
- An outline of virus structure 678
- Examples of pathogenic viruses 678
- Virus function and life history 678
- The host-virus interaction 679
- Resistance against viruses 679
- Viral glycoproteins 680
- HIV and AIDS 680
- Production of the disease 681
- Progress of infection 681

51 Basic principles of chemotherapy 682

- Neuromimetic inhibitors 682
- Disassembly 682
- Drugs acting through other mechanisms 682
- Biopharmaceutical antiviral drugs 682
- Other antiviral drugs 682
- Combination therapy for HIV 682
- Prophylaxis for new antiviral drugs 682
- Antiviral drugs 682
- Antiviral drugs 682
- Antiviral drugs 682

Section 6 Special topics

- 58 Harmful effects of drugs 733**
 - Overview 733
 - Classification of adverse effects 733
 - Adverse effects 733
 - Drug treatment 733

54 Antifungal drugs 690

- Overview 690
- Fungal and lung infections 690
- Drugs used to treat fungal infections 690
- Current status of antifungal drugs 690